Výsledky vyhledávání
- 1.KAISRLIKOVA, M.; KUNDRAT, D.; KORALKOVA, P.; TRSOVA, I.; LENERTOVA, Z.; VOTAVOVA, H.; DOSTALOVA MERKEROVA, M.; KREJCIK, Z.; VESELA, J.; VOSTRY, M.; SIMECKOVA, R.; STASTNA MARKOVA, M.; LAUERMANNOVA, M.; JONASOVA, A.; CERMAK, J.; DIVOKY, V.; BELICKOVA, M.G Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower‐risk myelodysplastic neoplasms. International journal of cancer. 2024, vol. 154, no. 9, s. 1652-1668. ISSN 0020-7136.
- 2.HRUSTINCOVA, A.; TRSOVA, I.; KREJCIK, Z.; KUNDRAT, D.; BELICKOVA, M.; KAISRLIKOVA, M.; VESELA, J.; KLEMA, J.; RYSAVY, P.; SUTTNAR, J.; HLAVACKOVA, A.; JONASOVA, A.; CERMAK, J.; DOSTALOVA MERKEROVA, M. SF3B1 mutations and their impact on cellular bioenergetics in myelodysplastic syndromes. Leukemia research. 2023, vol. 128, no. Supplement, s. 71. ISSN 0145-2126.
- 3.TRSOVA, I.; HRUSTINCOVA, A.; KREJCIK, Z.; KUNDRAT, D.; HOLOUBEK, A.; STAFLOVA, K.; JANSTOVA, L.; VANIKOVA, S.; SZIKSZAI, K.; KLEMA, J.; RYSAVY, P.; BELICKOVA, M.; KAISRLIKOVA, M.; VESELA, J.; CERMAK, J.; JONASOVA, A.; DOSTAL, J.; FRIC, J.; MUSIL, J.; DOSTALOVA MERKEROVA, M.G Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1. Molecular oncology. 2023, vol. 17, no. 12, s. 2565-2583. ISSN 1574-7891.
- 4.KAISRLIKOVA, M.; VESELA, J.; KUNDRAT, D.; VOTAVOVA, H.; DOSTALOVA-MERKEROVA, M.; KREJCIK, Z.; DIVOKY, V.; JEDLICKA, M.; FRIC, J.; KLEMA, J.; MIKULENKOVA, D.; STASTNA MARKOVA, M.; LAUERMANNOVA, M.; MERTOVA, J.; SOUKUPOVA MAALOUFOVA, J.; JONASOVA, A.; CERMAK, J.; BELICKOVA, M.G RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia. 2022, vol. 36, no. 7, s. 1898-1906. ISSN 0887-6924.
- 5.VOSTRÝ, M.; VESELÁ, J.; KAISRLÍKOVÁ, M.; MUCKSOVÁ. K.; ČERMÁK, J.; BELIČKOVÁ, M. Molekulárně genetická diagnostika hemoglobinopatií na ÚHKT. [Prezentováno: XXXIII. olomoucké hematologické dny: XXIII. konference ošetřovatelství a zdravotních laborantů: 12th symposium on advances in molecular hematology. Olomouc, 26.5.-28.5.2019.].
- 6.DOSTALOVA MERKEROVA, M.; KUNDRAT, D.; KREJCIK, Z.; HRUSTINCOVA, A.; TRSOVA, I.; SZIKSZAI, K.; KAISRLIKOVA, M.; VESELA, J.; KLEMA, J.; CERMAK, J.; BELICKOVA, M. Circular RNAs in myelodysplastic syndromes and impact of SF3B1 mutations on their expression.
- 7.VOTAVOVA, H.; URBANOVA, Z.; KUNDRAT, D.; DOSTALOVA MERKEROVA, M.; VOSTRY, M.; HRUBA, M.; CERMAK, J.; BELICKOVA, M.G Modulation of the immune response by deferasirox in myelodysplastic syndrome patients. Pharmaceuticals. 2021, vol. 14, no. 1, art. no. 41. ISSN 1424-8247.
- 8.KORALKOVA, P.; BELICKOVA, M.G; KUNDRAT, D.; DOSTALOVA MERKEROVA, M.; KREJCIK, Z.; SZIKSZAI, K.; KAISRLIKOVA, M.; VESELA, J.; VYHLIDALOVA, P.; STETKA, J.; HLAVACKOVA, A.; SUTTNAR, J.; FLODR, P.; STRITESKY, J.; JONASOVA, A.; CERMAK, J.; DIVOKY, V. Low plasma citrate levels and specific transcriptional signatures associated with quiescence of CD34+ progenitors predict Azacitidine therapy failure in MDS/AML patients. Cancers. 2021, vol. 13, no. 9, art. no. 2161. ISSN 2072-6694.
- 9.KAISRLIKOVA, M.; VESELA, J.; VOSTRY, M.; VOTAVOVA, H.; KUNDRAT, D.; DOSTALOVA MERKEROVA, M.; LAUERMANNOVA, M.; SOUKUPOVA MAALOUFOVA, J.; ZEMANOVA, Z.; JONASOVA, A.; CERMAK, J.; BELICKOVA, M. Mutations in RUNX1 gene contribute to the progression of lower-risk MDS patients by disrupting cellular protection against malignant transformation. Leukemia research. 2021, vol. 108, no. S1, s. S32. ISSN 0145-2126.
- 10.HRUBÁ, M. Význam sekvenování nové generace u MDS. Myelodysplastic syndrome news: časopis pro odborníky ve zdravotnictví. 2020, roč. 8, č. 1, s. 16-23. ISSN 2336-1093.